CFTR and cystic fibrosis: Similarly, in CF, patients are increasingly switching from older CFTR modulators (e.g., ivacaftor, lumacaftor/ivacaftor) to the more effective ETI, offering an opportunity to evaluate RW cost‐effectiveness and treatment optimization.